Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer.
作者信息
Mack Philip C, Gomez Jorge E, Rodilla Ananda M, Carreño Juan Manuel, Hsu Chih-Yuan, Rolfo Christian, Meshulami Noy, Moore Amy, Brody Rachel I, King Jennifer C, Treatman Jacquelyn, Lee Sooyun, Raskin Ariel, Srivastava Komal, Gleason Charles R, de Miguel-Perez Diego, Tcheou Johnstone, Bielak Dominika, Acharya Rashmi, Gerber David E, Rohs Nicholas, Henschke Claudia I, Yankelevitz David F, Simon Viviana, Minna John D, Bunn Paul A, García-Sastre Adolfo, Krammer Florian, Shyr Yu, Hirsch Fred R
机构信息
Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
Cancer Cell. 2022 Jun 13;40(6):575-577. doi: 10.1016/j.ccell.2022.04.012. Epub 2022 Apr 20.
Abstract
摘要
相似文献
1
Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer.肺癌患者中纵向新冠疫苗接种诱导的抗体反应和对奥密克戎的中和作用
Cancer Cell. 2022 Jun 13;40(6):575-577. doi: 10.1016/j.ccell.2022.04.012. Epub 2022 Apr 20.
2
Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization.肺癌患者新冠病毒疫苗接种的纵向分析：抗体反应和变异株特异性中和作用
J Clin Oncol. 2022 Nov 20;40(33):3787-3789. doi: 10.1200/JCO.22.01136. Epub 2022 Jun 27.
3
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.肺癌患者初次免疫和加强免疫后对 COVID-19 mRNA 疫苗的抗体反应：对 SARS-CoV-2 WT 病毒和奥密克戎变异株的反应性。
J Clin Oncol. 2022 Nov 20;40(33):3808-3816. doi: 10.1200/JCO.21.02986. Epub 2022 Jun 27.
4
Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.野生型 SARS-CoV-2 中和抗体的免疫活性会随着时间推移和变异株的不同而降低，但与诊断检测有很好的相关性。
Front Immunol. 2023 Feb 8;14:1055429. doi: 10.3389/fimmu.2023.1055429. eCollection 2023.
5
Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections.加强针接种后抗体反应较弱的个体更容易感染奥密克戎突破性感染。
Front Immunol. 2022 Jun 23;13:907343. doi: 10.3389/fimmu.2022.907343. eCollection 2022.
6
Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.青少年和成年人对 SARS-CoV-2 奥密克戎变异株的辉瑞（BNT162b2）疫苗诱导的抗体反应丧失。
J Virol. 2022 Sep 14;96(17):e0058222. doi: 10.1128/jvi.00582-22. Epub 2022 Aug 17.
7
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy.接受抑制性抗逆转录病毒疗法的 HIV 感染者接种三剂新冠肺炎疫苗后的抗体反应持久性。
AIDS. 2023 Apr 1;37(5):709-721. doi: 10.1097/QAD.0000000000003469. Epub 2022 Dec 22.
8
COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood.COVID-19 疫苗诱导母血和脐血中针对 SARS-CoV-2 奥密克戎变异株的中和效价较低。
Front Immunol. 2023 Jul 3;14:1211558. doi: 10.3389/fimmu.2023.1211558. eCollection 2023.
9
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.奥密克戎变异株对抗体介导的中和作用具有高度抗性：对控制 COVID-19 大流行的影响。
Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24.
10
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.康复者接种 SARS-CoV-2 疫苗可增强对奥密克戎亚变体 BA.1、BA.2 和 BA.5 的中和能力，且可通过血清学检测中的抗-S 抗体浓度进行预测。
Front Immunol. 2023 Apr 25;14:1170759. doi: 10.3389/fimmu.2023.1170759. eCollection 2023.
引用本文的文献
1
Impact of Cancer Subtype and Cancer Therapy Exposures on SARS-CoV-2 Outcomes in the Omicron and Subvariant Era.癌症亚型和癌症治疗暴露对奥密克戎及其亚型流行时代严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染结局的影响
Cancer Med. 2025 Jul;14(14):e71082. doi: 10.1002/cam4.71082.
2
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer.共价研究：新冠病毒mRNA疫苗在转移性肺癌长期存活患者开放标签队列中的免疫原性和反应原性
Vaccines (Basel). 2025 Mar 5;13(3):273. doi: 10.3390/vaccines13030273.
3
In the time of COVID-19: challenges, successes, and lessons learned from studies in cancer patients.在新冠疫情期间：癌症患者研究中的挑战、成功经验与教训
J Natl Cancer Inst. 2025 Aug 1;117(8):1547-1556. doi: 10.1093/jnci/djaf073.
4
Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals.基于腺病毒的黏膜严重急性呼吸综合征冠状病毒2刺突蛋白1疫苗可引发强大的全身和黏膜免疫，并在动物中预防疾病。
mBio. 2025 Jan 8;16(1):e0217024. doi: 10.1128/mbio.02170-24. Epub 2024 Dec 4.
5
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer.临床干预对肺癌患者SARS-CoV-2免疫的时间依赖性影响。
Vaccines (Basel). 2024 Jun 26;12(7):713. doi: 10.3390/vaccines12070713.
6
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.BA.5二价加强疫苗接种增强了肺癌患者对XBB.1.5、XBB.1.16和XBB.1.9变体的中和作用。
NPJ Vaccines. 2023 Nov 21;8(1):179. doi: 10.1038/s41541-023-00779-8.
7
The role of vaccines in the COVID-19 pandemic: what have we learned?疫苗在 COVID-19 大流行中的作用：我们学到了什么？
Semin Immunopathol. 2024 Jan;45(4-6):451-468. doi: 10.1007/s00281-023-00996-2. Epub 2023 Jul 12.
8
Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients.癌症患者 COVID-19 疫苗接种后针对 SARS-CoV-2 奥密克戎 BA.1 及其亚变体 BA.4/5 和 BQ.1.1 的体液反应和中和抗体的纵向数据。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10633-10644. doi: 10.1007/s00432-023-04961-2. Epub 2023 Jun 10.
9
Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review.肺癌患者接种新冠疫苗后对SARS-CoV-2的血清学反应：简短综述
Vaccines (Basel). 2023 May 11;11(5):969. doi: 10.3390/vaccines11050969.
10
Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.研究癌症患者接种第三和第四剂 COVID-19 疫苗的免疫反应效果和持久性：一项单臂临床试验。
Elife. 2023 Mar 28;12:e83694. doi: 10.7554/eLife.83694.
本文引用的文献
1
Three-dose vaccination elicits neutralising antibodies against omicron.三剂疫苗接种可引发针对奥密克戎的中和抗体。
Lancet. 2022 Feb 19;399(10326):715-717. doi: 10.1016/S0140-6736(22)00092-7. Epub 2022 Jan 19.
2
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.奥密克戎对抗体中和作用的逃逸显著。
Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23.
3
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.第三次BNT162b2疫苗接种对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎感染的中和作用
N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.
4
Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation.肺癌与严重急性呼吸综合征冠状病毒 2 感染：确定重要的研究知识空白。
J Thorac Oncol. 2022 Feb;17(2):214-227. doi: 10.1016/j.jtho.2021.11.001. Epub 2021 Nov 10.
5
Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer.评估有或无癌症的美国 COVID-19 患者的死亡率和不良结局。
JAMA Oncol. 2022 Jan 1;8(1):69-78. doi: 10.1001/jamaoncol.2021.5148.
6
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.单剂 SARS-CoV-2 mRNA 疫苗接种后血清阳性者的抗体反应。
N Engl J Med. 2021 Apr 8;384(14):1372-1374. doi: 10.1056/NEJMc2101667. Epub 2021 Mar 10.
7
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
8
Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis.COVID-19 感染癌症患者的临床特征和结局：系统评价和荟萃分析。
J Natl Cancer Inst. 2021 Apr 6;113(4):371-380. doi: 10.1093/jnci/djaa168.
9
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).实体瘤癌症患者 2019 年冠状病毒病（COVID-19）严重程度和死亡率的危险因素以及该疾病对癌症治疗的影响：一项法国全国性队列研究（GCO-002 CACOVID-19）。
Eur J Cancer. 2020 Dec;141:62-81. doi: 10.1016/j.ejca.2020.09.035. Epub 2020 Oct 8.
10
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.COVID-19 对癌症患者的临床影响（CCC19）：一项队列研究。
Lancet. 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9. Epub 2020 May 28.
Zotero 插件